That's our dream, of course, and the way we do that is to work with companies in Canada like Allen's company—that kind of company that's here in Canada—so that we can help facilitate those phase 1, phase 2, phase 3 studies here, and get it approved in Canada. Also during that whole process, as you point out, Mr. Cannings, we're actually being able to treat Canadian patients right now with therapies that are proving to be curative. So I think it's a good strategy.
On March 31st, 2022. See this statement in context.